When I look back the past week, I've ended up with this company as a bigger holding than I expected. I've bought shares every market day, since last Fri, the day I learned about the company. I've had to pay a bit of a higher price each day.
I'm absolutely at the risk size limit now. It won't be quick for the stock to settle down. A lot of shareholders wish they had sold when the market fleetingly offered them $5 post data, and many others who bought at prices lower than here will surely be happy with quick gains in a stock in which they lack a lot of conviction.
What the company has now is a future revenue stream; global expansion opportunities; and some chance of being acquired. The company is certain of it's filing for FDA approval in Q4, and we're now at a specific launch schedule...all of this uncertainty is gone.
It's a market size issue from here -- I think stock-picking institutional shareholders will slowly find their way over here, because of the relatively low risk vs higher reward.
Last Friday, I had to make a quick decision to buy, and those 3.8 shares quickly moved to 3.9 and it's been like that each time I've decided to buy more.
Within my portfolio I'm pretty happy to have this holding. CARA's approval will hit us badly, and we can see that CARA's share price is exuberant over TRVN's trial data, but I'm betting that much of this dour feelings are baked into the share price...nervous about this, but I'm realizing that the market is likely accounting for this risk at the prices the market was willing to sell to me.
We'll see...
News 
Market Data 
Discover 
